An example of a possible specialized application of metformin in cancer treatment. An example of a possible specialized application of metformin in cancer.

Slides:



Advertisements
Similar presentations
ASCO G.U Lawrence H. Einhorn.
Advertisements

Castrate-resistant prostate cancer (CRPC)
Slide 1 Presented By Mark Stein at 2014 ASCO Annual Meeting.
Prostate Cancer Int. 洪 毓 謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 100 Basic Principles of Cancer Chemotherapy.
Low dose chemotherapy with insulin (Insulin Potentiation Therapy) in combination with hormone therapy for treatment of castration resistant prostate cancer.
Annual prostate cancer symposium February 23, 2013 The Kimmel Cancer Center, Philadelphia, PA 2nd “ Novel Therapeutic Strategies for Prostate Cancer ”
Some Current Issues in the Management of Prostate Cancer Suman Chatterjee MD.
Predicting Subsequent Response to Hormone Therapy Following First-line Androgen Deprivation in Advanced Prostate Cancer S. Turner H. Gurney V. Gebski M.
Thiazolidinediones Inhibit Aromatase Activity in Human Granulosa Cells by Interfering with Androgen Binding to Aromatase Takako Araki M.D. Dimiter Avtanski.
Table 1. Characteristics of patients and the results of the log-rank test of prognostic factors Median (range) No. of patients No. of CRPC Median progression.
AR-V7 Splice Variant in Prostate Cancer : Taking Centre Stage
J Clin Oncol 31: © 2013 by American Society of Clinical Oncology GASTROENTEROLOGY 2012;143:897–912. Journal conference.
METHODS and STATISTICS
Volume 164, Issue 6, Pages (December 2000)
Patient Information Sheet
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
Copyright © 2012 American Medical Association. All rights reserved.
PHEN Clinical Trials Rally
Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand  Bannakij Lojanapiwat, Choosak Pripatnanont,
Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy.
Volume 60, Issue 2, Pages (August 2011)
The Role of Statistics in Clinical Trials
Presented By Luca Malorni at 2017 ASCO Annual Meeting
Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies  A. Vogel, R.D. Hofheinz, S. Kubicka, D. Arnold 
The Nurse View.
Metastatic HER2+ Breast Cancer: Resistance
Volume 61, Issue 6, Pages (June 2012)
Role of Chemotherapy in the Current Treatment Paradigm for Men With CRPC.
Claude C. Schulman, Jacques Irani, Juan Morote, Jack A
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.
Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.
Advances in the Treatment of Metastatic Prostate Cancer
Volume 189, Issue 1, Pages S45-S50 (January 2013)
Androgen Receptor Variants and Castration-resistant Prostate Cancer: Looking Back and Looking Forward  Takuma Uo, Cynthia Sprenger  European Urology 
Volume 71, Issue 1, Pages 1-3 (January 2017)
CEM FICICIOGLU, M.D, Ph.D.,AA.,MBA
Prostate Cancer Management: What Does the Future Hold?
Volume 73, Issue 6, Pages (June 2018)
Laurent Boccon-Gibod  European Urology Supplements 
Antihyperglycemic therapy in type 2 diabetes: general recommendations
Volume 73, Issue 5, Pages (May 2018)
Volume 61, Issue 6, Pages (June 2012)
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Figure 1 Differences in bladder cancer between genders
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer  Matthew R. Smith  European Urology Supplements 
Trends and Racial Differences in the Use of Androgen Deprivation Therapy for Metastatic Prostate Cancer  April P. Carson, PhD, Daniel L. Howard, PhD,
The Role of Obesity and Related Metabolic Disturbances in Cancers of the Colon, Prostate, and Pancreas  Edward Giovannucci, Dominique Michaud  Gastroenterology 
The Road to Quality Improvement in HER2-Positive Breast Cancer
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Clinical applications of CTCs and ctDNA as liquid biopsy for personalized medicine. Clinical applications of CTCs and ctDNA as liquid biopsy for personalized.
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Improving Flexibility and Quality of Life for Your Patients: A Must?
European Urology Oncology
Do Cancer Cells Care If Their Host Is Hungry?
Michael Lanuti, MD  The Journal of Thoracic and Cardiovascular Surgery 
William G. Nelson, Michael C. Haffner, Srinivasan Yegnasubramanian 
Nat. Rev. Urol. doi: /nrurol
Proposed spiral model for prostate cancer progression.
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Evaluating the Totality of Evidence
Antihyperglycemic therapy in adults with type 2 diabetes
Possible outcomes of therapeutic treatments using the spiral model.
Myc succeeds Akt activation and is required for growth of metastatic prostate cancer. Myc succeeds Akt activation and is required for growth of metastatic.
Top, NEPC biology is estimated to drive approximately 25% of the lethal prostate cancers indicated by the blue zone. Top, NEPC biology is estimated to.
Samuel Kim, MD  The Journal of Thoracic and Cardiovascular Surgery 
DHT-dependent phase of prostate cancer.
Presentation transcript:

An example of a possible specialized application of metformin in cancer treatment. An example of a possible specialized application of metformin in cancer treatment. Many contexts in which metformin may have a use in cancer treatment have been proposed. One example involves use with androgen deprivation therapy in prostate cancer. As discussed in the text, androgen deprivation has obvious benefit for men with metastatic prostate cancer, but this is temporary, and is associated with adverse effects related to androgen deficiency–induced hyperinsulinemia, including increased cardiovascular disease risk. As insulin may directly stimulate neoplastic growth of certain prostate cancers, or upregulate intratumoral testosterone synthesis, the hyperinsulinism of androgen deprivation may also contribute to progression to castration-resistant disease. If ongoing research shows that metformin attenuates the hyperinsulinemia associated with androgen deprivation, combined androgen deprivation and metformin may improve both tolerability and efficacy. Michael N. Pollak Cancer Discovery 2012;2:778-790 ©2012 by American Association for Cancer Research